Breaking News Instant updates and real-time market news.

ONCS

OncoSec

$1.73

-0.14 (-7.49%)

08:09
11/06/18
11/06
08:09
11/06/18
08:09

OncoSec reports preliminary data from KEYNOTE-695 trial of TAVO

OncoSec Medical reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO, or tavokinogene telseplasmid / IL-12, with intravenous KEYTRUDA, or pembrolizumab, in patients with unresectable, advanced melanoma. Eligible patients had refractory, locally advanced or metastatic disease defined as unresectable Stage III/IV metastatic melanoma that had definitively progressed on a full-course of anti-PD-1 treatment with KEYTRUDA, or pembrolizumab, or OPDIVO, or nivolumab. Two of the nine patients experienced a partial response and one patient had stable disease by RECIST v1.1. Tumor responses were noted in both treated and untreated lesions.

  • 06

    Nov

  • 07

    Nov

  • 27

    Nov

ONCS OncoSec
$1.73

-0.14 (-7.49%)

02/09/18
PIPR
02/09/18
INITIATION
Target $4
PIPR
Overweight
OncoSec initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started OncoSec Medical with an Overweight rating and $4 price target. The company's lead candidate ImmunoPulse in checkpoint inhibitor refractory metastatic melanoma "offers a differentiated approach," the analyst contends. He sees potential for $350M in peak U.S. revenues for IP IL-12 in this initial population following a 2020 launch.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $5
PIPR
Overweight
OncoSec price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for OncoSec Medical to $5 saying tavokinogene telseplasmid has demonstrated proof-of-concept data in relapsed/refractory melanoma. The analyst expects final Phase II OMS-100 monotherapy plus preliminary Phase IIb data at the Society for Immunotherapy of Cancer meeting in November. Depending upon the strength of data in Stage 2 of this trial, OncoSec may be able to seek accelerated approval in melanoma in 2020, Tenthoff tells investors in a research note after taking over coverage of the name. He maintains Piper's Overweight rating on OncoSec.
10/15/18
PIPR
10/15/18
NO CHANGE
Target $5
PIPR
Overweight
Piper reiterates Overweight on OncoSec with $5 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on OncoSec Medical with a $5 price target after the company announced it initiated a Phase II study of tavokinogene telseplasmid plus Keytruda in and triple negative breast cancer patients who have received one prior chemo or immunotherapy with preliminary data in 2019. The primary driver for OncoSec shares remains the Stage 1 Phase IIb Pisces data on tavokinogene telseplasmid plus Keytruda in PD-1 refractory melanoma in November, Tenthoff tells investors in a research note. He points out that depending on the data, OncoSec may initiate Stage 2 of the study, which could serve as the basis for accelerated approval in melanoma in 2020.

TODAY'S FREE FLY STORIES

APTX

Aptinyx

$5.64

-0.07 (-1.23%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Hot Stocks
Aptinyx doses first patient in Phase 2 NYX-783 study »

Aptinyx announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.11

-0.11 (-2.11%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Conference/Events
PLx Pharma to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBRV

Nabriva Therapeutics

$2.08

0.045 (2.22%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
Nabriva Therapeutics announces FDA acceptance of lefamulin NDAs »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

WORX

SCWorx

$5.74

-0.07 (-1.20%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
SCWorx announces new customer service agreement »

SCWorx has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$17.56

0.07 (0.40%)

, JPM

JPMorgan

$105.56

3.14 (3.07%)

07:25
02/19/19
02/19
07:25
02/19/19
07:25
Hot Stocks
Arconic announces $700M accelerated share repurchase agreement »

Arconic (ARNC) announced…

ARNC

Arconic

$17.56

0.07 (0.40%)

JPM

JPMorgan

$105.56

3.14 (3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Hot Stocks
Intercept intends to file for OCA regulatory approval in U.S., Europe in 2H19 »

"We are thrilled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CNMD

Conmed

$71.94

0.73 (1.03%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Upgrade
Conmed rating change  »

Conmed reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 18

    May

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

, TLRY

Tilray

$76.46

-0.2 (-0.26%)

07:23
02/19/19
02/19
07:23
02/19/19
07:23
Recommendations
Aurora Cannabis, Tilray, CV Sciences, Cronos Group, General Cannabis, CannTrust Holdings, Aphria, MediPharm Labs, Canopy Growth, India Globalization Capital analyst commentary  »

Moody's price target…

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

TLRY

Tilray

$76.46

-0.2 (-0.26%)

CVSI

CV Sciences

$0.00

(0.00%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

CANN

General Cannabis

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

APHA

Aphria

$9.58

0.49 (5.39%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

IGC

India Globalization Capital

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept jumps 36% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Intercept announces results from Phase 3 REGENERATE study »

Intercept announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Earnings
Noble Midstream reports Q4 EPS $1.00, consensus $1.03 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

, UPS

UPS

$110.89

-0.91 (-0.81%)

07:20
02/19/19
02/19
07:20
02/19/19
07:20
Downgrade
XPO Logistics, UPS, FedEx, C.H. Robinson, Amazon.com rating change  »

Morgan Stanley downgrades…

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

UPS

UPS

$110.89

-0.91 (-0.81%)

FDX

FedEx

$179.20

-4.74 (-2.58%)

CHRW

C.H. Robinson

$91.43

0.74 (0.82%)

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:19
02/19/19
02/19
07:19
02/19/19
07:19
Hot Stocks
Cooper Tire sees modest unit volume growth compared to 2018 »

Sees improving operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:18
02/19/19
02/19
07:18
02/19/19
07:18
Hot Stocks
Cooper Tire sees Q1 operating profit margin lower than Q1 »

Management expects Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Recommendations
XPO Logistics analyst commentary  »

Deutsche puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OPTN

Optinose

$7.40

0.23 (3.21%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Hot Stocks
Optinose announces four additional Xhance patents from USPTO »

Optinose announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$62.77

0.19 (0.30%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Downgrade
Sensient rating change  »

Sensient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

CRSP

Crispr Therapeutics

$31.62

0.65 (2.10%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Hot Stocks
Crispr Therapeutics, StrideBio announce expanded strategic collaboration »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

Ceva

$28.91

1.23 (4.44%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Ceva announces collaboration to add C-V2X Rel. 14/15 support to the CEVA-XC DSP »

CEVA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.62

-0.045 (-2.70%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Plug Power begins production of next gen class 1 material handling equipment »

Plug Power announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Earnings
Cooper Tire reports Q4 EPS ex-items 66c, consensus 58c »

Reports Q4 revenue $770M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

ARAV

Aravive

$4.95

0.2 (4.21%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Hot Stocks
Aravive receives additional $2.6M disbursement from CPRIT for AVB-S6-500 »

Aravive announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CASI

Casi Pharmaceuticals

$3.59

0.07 (1.99%)

, SPPI

Spectrum

$11.71

0.03 (0.26%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Hot Stocks
Casi Pharmaceuticals: NMPA approves CTA for trial of ZEVALIN »

CASI Pharmaceuticals…

CASI

Casi Pharmaceuticals

$3.59

0.07 (1.99%)

SPPI

Spectrum

$11.71

0.03 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

PHIIK

PHI Inc

$3.10

0.01 (0.32%)

07:12
02/19/19
02/19
07:12
02/19/19
07:12
Hot Stocks
PHI Inc shareholder Stabosz calls on company to address Debtwire story »

One of PHI, Inc.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.